Independent Replication and Drug-specificity of an Antidepressant Response Polygenic Risk Score

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Trial registration: International Study to Predict Optimised Treatment - in Depression (iSPOT-D) ClinicalTrials.gov Identifier: NCT00693849. URL: http://clinicaltrials.gov/ct2/show/NCT00693849?term=International+Study+to+Predict+Optimized+Treatment+for+Depression&rank=1 and the EudraCT database: 2008-004122-17 This study was approved by the institutional review boards at all of the participating sites, the IRBNijmegen (IRBN2008009) and this trial was registered with ClinicalTrials.gov

Funding Statement

The research is funded by Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, The Netherlands.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

In the submission system, your ethics declaration states: "The study is conducted according to the principles of the Declaration of Helsinki 2008 (World Medical Association Declaration of Helskini: http://www.wma.net/en/30publications/10policies/b3/index.html). The International Conference on Harmonization (ICH) guidelines (http://www.ich.org/home.html) and/or in compliance with the laws and regulations of the country in which the research is conducted (Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, The Netherlands), including the "Good Clinical Practice" principles in the US FDA Code of Federal Regulations. Institutional Review Board (IRB) approval from Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, The Netherlands, was obtained prior to patient enrolment at all clinical sites. Prior to undertaking any study-related procedures, each participant received a verbal and written explanation of study aims, methods, potential hazards and benefits from investigators, and provided written informed consent. The investigator notifies the Institutional Review Board or Independent Ethics Committee (in writing) of (serious adverse events) SAEs as soon as is practical where this is required by local regulatory authorities and in accordance with the local institutional policy. In accordance with the European Union Clinical Trials Directive (2001/20/EC), the Sponsor or its designee notifies the Ethics Committees of the concerned Member States of SAEs that are unexpected and possibly attributable to the treatment medication. In all countries, SAEs are reported in accordance with the regulations governing expedited reporting for registered products. SAE reporting is monitored by the Clinical Research Organization and all SAEs are reviewed by the (Data Safety Monitoring Board) DSMB.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes